Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update ivps42019-05-15T15:43:49-05:00May 15th, 2019|Press Release| Read More
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019 ivps42019-04-30T18:19:42-05:00May 7th, 2019|Press Release| Read More
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation ivps42019-04-23T15:51:25-05:00April 24th, 2019|Press Release| Read More
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019 ivps42019-03-28T13:05:13-05:00April 3rd, 2019|Press Release| Read More
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation ivps42019-03-29T12:54:22-05:00April 2nd, 2019|Press Release| Read More
Achieve Life Sciences to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 ivps42019-03-15T13:39:47-05:00March 18th, 2019|Press Release| Read More
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update ivps42019-03-13T17:01:42-05:00March 14th, 2019|Press Release| Read More
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019 ivps42019-03-01T17:18:29-05:00March 5th, 2019|Press Release| Read More
Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting ivps42019-02-19T17:33:44-05:00February 22nd, 2019|Press Release| Read More
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation ivps42019-02-19T15:59:12-05:00February 20th, 2019|Press Release| Read More